Drug profile

The FDA adverse-event record for Gentamicin Sulfate, Betamethasone Valerate

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Gentamicin Sulfate, Betamethasone Valerate. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
11.8%
death-coded share
Dog
most-reported species
3
Anaemia NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
2
Deaths Reported
11.8%
Death Rate

Active Ingredients

Gentamicin Sulfate, Betamethasone Valerate

Administration Routes

TopicalUnknownAuricular (Otic)

Species Affected

Dog 14
Cat 3

Most Affected Breeds

Shih Tzu 3
Domestic Shorthair 2
Dachshund (unspecified) 1
Retriever (unspecified) 1
Domestic Longhair 1
Beagle 1
Retriever - Golden 1
Spaniel (unspecified) 1
Hound - Basset 1
Chihuahua 1

Most Reported Reactions

Anaemia NOS 3
Other abnormal test result NOS 3
Decreased appetite 3
Lack of efficacy - NOS 3
Not eating 3
Vomiting 2
Bacterial skin infection NOS 2
Overdose 2
INEFFECTIVE, ANTIBIOTIC 2
PR-SKIN, LESION(S) 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Erythema (for urticaria see Immune SOC) 2

Outcome Breakdown

Ongoing
9 (52.9%)
Outcome Unknown
4 (23.5%)
Recovered/Normal
2 (11.8%)
Died
1 (5.9%)
Euthanized
1 (5.9%)

Gentamicin Sulfate, Betamethasone Valerate Adverse Event Insights

17 reports name Gentamicin Sulfate, Betamethasone Valerate; 2 recorded a death outcome (11.8% of reported events, not a population-level mortality rate). Active ingredient: Gentamicin Sulfate, Betamethasone Valerate. Administration routes: Topical, Unknown, Auricular (Otic).

By species: Dog (14 reports), Cat (3 reports). By breed: Shih Tzu (3), Domestic Shorthair (2), Dachshund (unspecified) (1).

Leading clinical signs: Anaemia NOS (3), Other abnormal test result NOS (3), Decreased appetite (3), Lack of efficacy - NOS (3). Outcome, 17 coded reports: Ongoing leads at 52.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.